What is uMed?
uMed is dedicated to enhancing life science research by bridging the gap between patient experience and rigorous data. They offer a modular suite of decentralized study services, including patient recruitment and data collection, aimed at facilitating faster and more representative evidence generation. Their solutions cater to pharmaceutical teams, clinical trial teams, and healthcare professionals, ensuring efficient study workflows and access to diverse patient cohorts. With a focus on security and compliance, uMed prioritizes patient trust while enabling innovative medical research.
How much funding has uMed raised?
uMed has raised a total of $12.4M across 1 funding round:
Other Financing Round
$12.4M
Other Financing Round (2023): $12.4M with participation from 11.2 Capital, Albion Ventures, Delin Ventures, and Playfair Capital
Key Investors in uMed
11.2 Capital
11.2 Capital is a Venture Capital firm that focuses on emerging technologies, particularly in AI, cybersecurity, and robotics.
Albion Ventures
AlbionVC is the technology investment arm of Albion Capital Group LLP, specializing in high-growth B2B software and technology-enabled services, with a focus on early-stage investments.
Delin Ventures
Delin Ventures is a mission-driven investor focused on transforming lives through innovations in life sciences and technology, investing in and building companies in cell therapy and the tech sector.
What's next for uMed?
The substantial enterprise-level backing and recent strategic investment position uMed for accelerated growth and expansion of its decentralized study services. This capital infusion is expected to fuel further development of their platform, enhance patient recruitment capabilities, and broaden their reach within the pharmaceutical and healthcare sectors. The company's focus on secure and compliant data collection will likely remain a cornerstone as they scale their operations and pursue further innovation in medical research.
See full uMed company page
